Core 2: Translational Biospecimens and Imaging Biomarkers

核心2 翻译生物样品与成像生物标记物核心 摘要 翻译生物显微镜和成像生物标记物核心组件(核心2)是一个独特的、集中的 支持从接受放射治疗的患者收集生物样品和成像数据的资源，并将提供 样品的采集、加工和共享。这些活动将针对登记参加临床治疗的患者进行 在两个合作地点使用标准化方案和程序进行实验性放射治疗试验。这 CORE将1)获得肿瘤患者的自愿知情同意，这些患者将接受或接受评估 放射治疗允许：(I)识别、存储和使用患者的血液、组织和临床信息 为了研究目的，(2)将临床信息与#年进行的关于生物检疫的研究结果联系起来 与核心1合作，(3)分享和公布科学研究产生的未查明身份的数据；2) 为采集、注释和存储图像提供全面、安全和标准化的流程 来自患者的生物标志物和生物标本将接受、接受或评估 马萨诸塞州总医院(MGH)和德克萨斯大学MD安德森癌症中心的放射治疗 中心(UTMDACC)；以及3)促进基础研究和翻译研究的开展，以进一步个性化 利用临床护理过程中收集的影像和血液生物标志物与临床一起进行治疗 数据。核心2将支持项目中的创新方法，如多重蛋白质分析和 免疫表型和新的成像方法。核心将促进基于以下方面的翻译生物标志物研究 了解质子与光子放射治疗后的固有肿瘤生物学和淋巴细胞变化， 在粒子治疗领域，它在很大程度上仍然没有特征。此外，支持项目1，使用 以获得关于质子治疗对正常组织的影响的信息 DOGET和LET都是高度创新的，基于人工智能的MRI自动分割算法的开发也是如此 和XNAT图像分析流水线，包括基于体素的肝脏功能成像分析、中央 神经系统和肺部。核心2‘S的支持将使我们能够以全新的方式理解免疫系统的相互作用 项目2中的质子与光子放射治疗系统。项目3将依靠核心2为人类提供 用于建立PDX模型的组织标本和可用于临床前研究的细胞系目录 跨机构，从而利用MGH和UTMDACC的优势。酷睿2的优势在于它 利用两个癌症中心独特的患者群体和能力。MGH网站将做出贡献 在40多项临床试验中流通生物标记物研究方面拥有20年的专业知识，而UTMDACC网站将 在领先的全国多中心质子与光子协作疗法方面提供丰富的经验 临床和转化性研究，包括患者登记、患者同意、 和生物制品收藏。这两个网站还将提供卓越的成像生物标记物研究能力和 CORE将促进这些数据集在两个中心之间的转移。

CORE 2 TRANSLATIONAL BIOSPECIMEN AND IMAGING BIOMARKER CORE SUMMARY The Translational Biospecimen and Imaging Biomarker Core Component (Core 2) is a unique, centralized resource to support biospecimen and imaging data collection from radiation-treated patients and will provide sample collection, processing, and sharing. These activities will be carried out for patients enrolled in clinical trials of experimental radiotherapy at the two partnering sites using standardized protocols and procedures. This core will 1) obtain voluntary, informed consent from oncology patients who will undergo or be evaluated for radiation therapy to allow for: (i) identification, storage, and use of patients’ blood, tissue, and clinical information for research purposes, (ii) linkage of clinical information to results from research performed on biospecimens in cooperation with core 1, (iii) sharing and publication of de-identified data generated from scientific study; 2) provide a comprehensive, secure and standardized process for collecting, annotating and storing imaging biomarkers and biological specimens from patients who have undergone, will undergo or be evaluated for radiotherapy at the Massachusetts General Hospital (MGH) and the University of Texas MD Anderson Cancer Centers (UTMDACC); and 3) facilitate the conduct of basic and translational research to further personalize therapy using imaging and blood biomarkers collected during the course of clinical care together with clinical data. Core 2 will support innovative approaches in the projects, such as multiplexed protein analyses and immunophenotyping and new imaging methods. The Core will facilitate translational biomarker studies based on understanding of intrinsic tumor biology and lymphocyte alterations following proton versus photon radiotherapy, which remains largely uncharacterized in the field of particle therapy. Moreover, supporting Project 1, the use of imaging biomarkers to gain information on the effects of proton therapy on normal tissues as a function of both dose and LET is highly innovative, as is the development of AI-based autosegmentation algorithms for MRI and XNAT image analysis pipeline, including the voxel-based analysis of functional imaging for liver, central nervous system and lung. Core 2’s support will enable novel understanding of the interaction of the immune system with proton versus photon radiotherapy in Project 2. Project 3 will rely on Core 2 to provide human tissue specimen for the creation of PDX models and a catalogue of cell lines available for preclinical research across institutions, thereby harnessing the strengths of MGH and UTMDACC. The strength of Core 2 is that it leverages the unique patient population and capabilities at the two Cancer Centers. The MGH site will contribute 20 years of expertise in circulating biomarker studies in over 40 clinical trials, while the UTMDACC site will provide extensive experience in leading nationwide multicenter collaborative proton versus photon therapy clinical and translational research that includes standardized procedures of patient enrollment, patient consent, and biospecimen collections. Both sites will also provide superb imaging biomarker study capabilities and the core will facilitate transfer of these datasets between the two centers.